OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Monk on Transformative KEYNOTE-826 Data in Frontline Cervical Cancer

September 18th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

September 17th 2021

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

September 17th 2021

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

Dr. Van Rhee on the Clinical Implications of CAR T-Cell Therapy in Relapsed/Refractory Myeloma

September 17th 2021

Frits van Rhee, MD, PhD, discusses the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Dr. Baljevic on the FDA Approval of the ICARIA-MM Regimen in Relapsed/Refractory Multiple Myeloma

September 16th 2021

Muhamed Baljevic, MD, discusses the FDA approval of isatuximab-irfc in combination with pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma.

Dr. Wang on the Significance of p53 Mutations in MCL

September 16th 2021

Michael Wang, MD, discusses the significance of p53 mutations in mantle cell lymphoma.

Dr. Patel on Mitigating CAR T-Cell Therapy­–Related CRS in Multiple Myeloma

September 16th 2021

Krina K. Patel, MD, MSc, discusses mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.

Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer

September 16th 2021

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Dr. Rodriguez on the Role of Immunotherapy in ES-SCLC

September 16th 2021

Estelamari Rodriguez, MD, MPH, discusses the role of immunotherapy in extensive-stage small cell lung cancer.

Dr. Anderson on the Challenges Faced With CAR T-Cell Therapy in Myeloma

September 16th 2021

Larry Anderson, MD, PhD, discusses the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC

September 15th 2021

Collin Blakely MD, PhD, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Dr. Shah on the Current State of Cellular Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

Dr. Pecot on Selecting Between Available Targeted Therapies in NSCLC

September 15th 2021

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.

Dr. Kahl on Patient Selection for Intensive Vs Non-Intensive Treatment in MCL

September 15th 2021

Brad S. Kahl, MD, discusses patient selection for intensive vs non-intensive treatment strategies in mantle cell lymphoma.

Dr. Shah on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Dr. Ready on the Role of Frontline Chemoimmunotherapy in Lung Cancer

September 14th 2021

Neal E. Ready, MD, PhD, discusses the role of frontline chemoimmunotherapy in lung cancer.

Dr. Costa on the Patients Included in the OlympiA Trial in HER2- Breast Cancer

September 14th 2021

Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.

Dr. Marshall on Considerations for Third-Line Therapeutic Options in CRC

September 14th 2021

John L. Marshall, MD, discusses factors to consider in the third-line treatment setting for patients with colorectal cancer.

Dr. Mogal on Patient Selection for Cytoreductive Surgery in CRC

September 13th 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the importance of patient selection for cytoreductive surgery in colorectal cancer with peritoneal involvement.

Dr. Sborov on the Toxicities Associated With Novel Therapies in Multiple Myeloma

September 13th 2021

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

NEXT PAGE
PREVIOUS PAGE